Alex Thompson
Stock Analyst at Stifel
(4.06)
# 568
Out of 5,161 analysts
39
Total ratings
56.76%
Success rate
12.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Buy | $56 → $85 | $63.79 | +33.25% | 3 | Mar 5, 2026 | |
| CLDX Celldex Therapeutics | Reiterates: Buy | $58 → $68 | $29.88 | +127.58% | 1 | Feb 26, 2026 | |
| ALMS Alumis | Initiates: Buy | $44 | $25.03 | +75.79% | 1 | Feb 25, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $5 | $2.03 | +146.31% | 1 | Feb 25, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $229.01 | +11.79% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $708.85 | +76.06% | 5 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $80.32 | -19.07% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $27.55 | -9.26% | 4 | Sep 12, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $13.95 | +57.71% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $77.50 | -29.03% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $16.71 | +115.44% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $36.51 | +64.34% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $49 | $31.99 | +53.17% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $40.41 | +33.63% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $17.03 | +305.17% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $3.51 | -71.51% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $28.41 | +40.80% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $24.99 | +36.05% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.41 | +2,240.43% | 1 | Dec 14, 2022 |
AnaptysBio
Mar 5, 2026
Maintains: Buy
Price Target: $56 → $85
Current: $63.79
Upside: +33.25%
Celldex Therapeutics
Feb 26, 2026
Reiterates: Buy
Price Target: $58 → $68
Current: $29.88
Upside: +127.58%
Alumis
Feb 25, 2026
Initiates: Buy
Price Target: $44
Current: $25.03
Upside: +75.79%
Palisade Bio
Feb 25, 2026
Initiates: Buy
Price Target: $5
Current: $2.03
Upside: +146.31%
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $229.01
Upside: +11.79%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $708.85
Upside: +76.06%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $80.32
Upside: -19.07%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $27.55
Upside: -9.26%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $13.95
Upside: +57.71%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $77.50
Upside: -29.03%
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $16.71
Upside: +115.44%
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $36.51
Upside: +64.34%
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $31.99
Upside: +53.17%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $40.41
Upside: +33.63%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $17.03
Upside: +305.17%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $3.51
Upside: -71.51%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $28.41
Upside: +40.80%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $24.99
Upside: +36.05%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.41
Upside: +2,240.43%